enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Stock Information for enVVeno Medical Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About enVVeno Medical Corporation

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
enVVeno Medical Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.